| T34 |
0-543 |
Sentence |
denotes |
In response to the above statement, the European Society of Cardiology on March 13 and the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America endowed a common statement on March 17 which mentioned that “since there is no scientific evidence behind ceasing the usage of ACEi and angiotensin type II receptor blockers (ARBs) for the patients affected by COVID-19 possessing other comorbidities such as high blood pressure, diabetes mellitus, cardiovascular problems and renal diseases” [11]. |
